321 related articles for article (PubMed ID: 22352729)
1. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
Doroshow JH
Curr Pharm Biotechnol; 2012 Aug; 13(10):1949-56. PubMed ID: 22352729
[TBL] [Abstract][Full Text] [Related]
2. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
3. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
4. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
Swain SM; Vici P
J Cancer Res Clin Oncol; 2004 Jan; 130(1):1-7. PubMed ID: 14564513
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Mouridsen HT; Langer SW; Buter J; Eidtmann H; Rosti G; de Wit M; Knoblauch P; Rasmussen A; Dahlstrøm K; Jensen PB; Giaccone G
Ann Oncol; 2007 Mar; 18(3):546-50. PubMed ID: 17185744
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
Kane RC; McGuinn WD; Dagher R; Justice R; Pazdur R
Oncologist; 2008 Apr; 13(4):445-50. PubMed ID: 18448560
[TBL] [Abstract][Full Text] [Related]
9. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
10. Totect: a new agent for treating anthracycline extravasation.
Schulmeister L
Clin J Oncol Nurs; 2007 Jun; 11(3):387-95. PubMed ID: 17623623
[TBL] [Abstract][Full Text] [Related]
11. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
Tyson AM; Gay WE
Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane in anthracycline extravasation.
Langer SW; Sehested M; Jensen PB; Buter J; Giaccone G
J Clin Oncol; 2000 Aug; 18(16):3064. PubMed ID: 10944144
[No Abstract] [Full Text] [Related]
14. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide.
Prescrire Int; 2009 Feb; 18(99):6-8. PubMed ID: 19382398
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
Sepe DM; Ginsberg JP; Balis FM
Oncologist; 2010; 15(11):1220-6. PubMed ID: 21051660
[TBL] [Abstract][Full Text] [Related]
16. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
17. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
18. Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin.
Conde-Estévez D; Saumell S; Salar A; Mateu-de Antonio J
Anticancer Drugs; 2010 Sep; 21(8):790-4. PubMed ID: 20671512
[TBL] [Abstract][Full Text] [Related]
19. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Jensen JN; Lock-Andersen J; Langer SW; Mejer J
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(3):174-5. PubMed ID: 12841619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
